After encouraging data on transthyretin amyloidosis therapy, Oppenheimer significantly raised Intellia Therapeutics' price target. Menawhile, CMS Energy saw its PT cut by RBC following the sale of Enerbank USA unit to regions. Apple and Fedex are also included in today's selection of analyst recommendations.
Apple: UBS reiterates its Buy rating. The target price is still set at USD 155.